Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.

Abstract: Simplification of a preparation step of a cell population used for the treatment of ischemic diseases, and provision of a cell population that shows more effective treatment are shown. A method of producing a cell population wherein a vascular endothelial progenitor cell and/or an anti-inflammatory macrophage are/is enriched, including cultivating a mononuclear cell derived from bone marrow, cord blood or peripheral blood in a serum-free medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and proliferating vascular endothelial progenitor cell from the cell; and a cell population obtained by the method are shown.

Abstract: A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

Abstract: The invention provides a method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells by contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. The invention also provides an agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method, as well as an agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor, and combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.

Abstract: In imaging analysis of a living body, a Region Of Interest (ROI) is set on the basis of the state of radiopharmaceutical accumulation. An example for setting an ROI includes: performing first transformation for anatomically standardizing, with the use of a positive template, a nuclear medicine image acquired by applying a radiopharmaceutical to a subject; performing second transformation for anatomically standardizing, with the use of a negative template, the nuclear medicine image; calculating a degree of similarity between a first anatomical standardization image acquired by the first transformation and the positive template; calculating a degree of similarity between a second anatomical standardization image acquired by the second transformation and the negative template; and applying, to an ROI template, inverse transformation of the first transformation or the second transformation, whichever has the higher of the calculated degrees of similarity, in order to set the ROI.

Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.